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ABSTRACT
Background: Colchicine poisoning is commonly lethal. Colchicine-specific Fab fragments increase rat
urinary colchicine clearance and have been associated with a good outcome in one patient. We aimed
to develop a porcine model of colchicine toxicity to study the pharmacokinetics and efficacy of ovine
Fab.
Methods: A G€ottingen minipig critical care model was established and serial blood samples taken for
colchicine and Fab pharmacokinetics, clinical chemistry, and haematology. Animals were euthanised
when the mean arterial pressure fell below 45mmHg without response to vasopressor, or at study
completion.
Results: Initial studies indicated that oral dosing produced variable pharmacokinetics and time-to-
euthanasia. By contrast, intravenous infusion of 0.25mg/kg colchicine over 1 h produced reproducible
pharmacokinetics (AUC0–20 343 [SD¼ 21] mg/L/h), acute multi-organ injury, and cardiotoxicity requiring
euthanasia a mean of 22.5 (SD¼ 3.2) h after dosing. A full-neutralising equimolar Fab dose given 6h after
the infusion (50% first hour, 50% next 6 h [to reduce renal-loss of unbound Fab]) produced a 7.35-fold
increase in plasma colchicine (AUC0–20 2,522 [SD¼ 14] mg/L/h), and removed all free plasma colchicine,
but did not prevent toxicity (euthanasia at 29.1 [SD¼ 3.4] h). Earlier administration over 1 h of the full-
neutralising dose, 1 or 3 h after the colchicine, produced a 12.9-fold (AUC0–20 4,433 [SD¼ 607] mg/L/h)
and 6.0-fold (AUC0–20 2,047 [SD¼ 51] mg/L/h) increase in plasma colchicine, respectively, absence of free
plasma colchicine until 20 h, and survival to study end without marked cardiotoxicity.
Conclusions: Colchicine-specific Fab given early, in equimolar dose, bound colchicine, eliciting its
movement into the blood, and preventing severe toxicity. Clinical studies are now needed to deter-
mine how soon this antidote must be given to work in human poisoning.
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Introduction
Colchicine is used for the treatment of gout, familial
Mediterranean fever, pericarditis, Behc¸et’s disease and
increasingly for ischaemic heart disease [1–4]. It inhibits
microtubule polymerization by binding to tubulin, preventing
mitosis, and inhibiting neutrophil function. It has a narrow
therapeutic index, resulting in severe toxicity after overdose,
especially after intravenous (IV) administration or intentional
poisoning [5–9]. Poisoning results in initial gastrointestinal
effects that last for around 24 h and may be followed by mul-
tiorgan dysfunction or death from cardiogenic shock, usually
within 48–96 h [8].
There is no licensed therapy, with current care revolving
around supportive intensive care. Fab fragments [10] against
colchicine were raised experimentally in the 1980–90s in
France [10,11] and used on a compassionate basis in at least
one patient [12]. They are now being produced commercially
in sheep and have been tested in a rodent model, showing
increased elimination of colchicine [13]. Ovine colchicine Fab
fragments have not yet been studied in humans. Before this
can happen, a pre-clinical model of colchicine poisoning simi-
lar to human poisoning is needed in which anti-colchicine
Fab can be tested, to explore efficacious dosing and timing.
Pigs have been identified as good models for toxicology
studies, offering similarities with human toxicity [14–16].
However, no pig model has been established for colchicine
poisoning and the toxic dose is not known. Reviewing colchi-
cine toxicity in humans, Harris and Gillett concluded that
survival was typical with doses of<0.5mg/kg while death
was almost inevitable with doses>0.8mg/kg, although
acknowledging multiple reports of fatalities after exposure
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to<0.5mg/kg [6]. Rats probably do not offer an appropriate
model for human toxicity because they are highly resistant
to colchicine poisoning with an LD50> 25mg/kg following
oral dosing [17].
We therefore established a model of acute colchicine poi-
soning in Gottingen minipigs, initially testing oral then IV
administration. This model showed that early administration
of colchicine Fab produced effective redistribution of colchi-
cine from tissues into the vascular space and prevented
lethal colchicine toxicity. A clinical study is now required in
human patients to assess the appropriate dose and max-
imum interval to effective therapy.
Methods
Animals and ethics
Experiments involved male G€ottingen minipigs (Ellegaard
Minipigs ApS, Dalmose, DK) with mean body mass 30.4 (SD
3.1) kg, n¼ 14. Animals were barrier bred, shown to be free
of infection before shipment, and treated in accordance with
the Animals (Scientific Procedures) Act of 1986. This study
was performed under Home Office Licence after institutional
ethics review.
Colchicine and anti-colchicine fab fragments
Colchicine (Abcam, Cambridge, UK) solutions were made up
in sterile water for injection at 1.0mg/mL and filter sterilised
using a 0.2-mm in-line filter. Colchicine containers were
wrapped in metal foil and stored in the dark to prevent pho-
todegradation. Solutions were diluted to 0.5 and 0.0625mg/
mL for oral and IV administration, respectively, and injected
volumes adjusted to give the required dose (mL/kg) based
on the animal’s body mass on the study day. The dose varied
from 0.25 to 1.0mg/kg. Oral doses were given via nasogastric
tube by bolus push using a 60-mL catheter tip syringe; IV
doses were infused over 1 h.
Anti-colchicine Fab (ColchiBIND) was supplied as a solu-
tion in 10mL ampoules by Micropharm Ltd, with each con-
taining sufficient Fab to neutralise approximately 0.2mg
colchicine. The average affinity constant (Ka) of the ovine
Fab was 3.16 1011 M1 (Micropharm Ltd, Unpublished). The
Fab volume administered was varied according to the pig’s
body mass on the study day. The ColchiBIND solution was
drawn up into 50mL syringes fitted with a 0.2-mm in-line fil-
ter immediately before infusion.
Study design
Drug-naive animals were kept in pens and acclimatised under
the care of institutional veterinary surgeons before the study.
Animals were fed a standard diet but fasted overnight pre-
ceding the study; water was available freely. Animals were
weighed on the morning of the study.
The experiment was conducted in two phases, with the
first phase being used to identify a toxic lethal dose with sur-
vival lasting greater than 24 h and death from apparent
cardiotoxicity. Based on the proposed human lethal dose of
colchicine being between 0.5 and 1.0mg/kg, we used two
single doses of oral colchicine (0.5 or 1.0mg/kg). The second
phase was used to study the pharmacokinetic (PK) and clin-
ical effects of anti-colchicine Fab on lethal colchicine toxicity,
using 1 of 2 single doses of intravenous colchicine (0.25 or
1.0mg/kg). We included the lower dose in case intravenous
colchicine was more toxic than orally administered colchicine.
Once the model was established, pharmacokinetic (PK) and
clinical effects of therapeutic administration of ovine colchi-
cine Fab fragments were evaluated at various times and infu-
sion durations after administration of a toxic intravenous
dose of colchicine.
To reduce bias, animals were allocated to treatment groups
using a random number list; allocation could not be predicted
before randomization. No data were available for calculating
group sizes in this model; however, the use of anti-colchicine
Fab at different times post poisoning offered a temporal basis
for testing clinical efficacy as well as assessing the PK.
Anaesthesia and instrumentation
Studies began each day at around 07:30. Studies using oral
administration were planned to last up to 60 h; after the
switch to IV colchicine, the studies lasted for up to 48 h. The
methods of anaesthesia induction, central vascular access,
and instrumentation together with continual cardiovascular
and respiratory monitoring of animals have been described
previously [18].
Experimental protocol
After a 30-min stabilization period for the pigs after instru-
mentation, colchicine solution was given by oral bolus dose
via NG tube (0.5 and 1.0mg/kg) or by IV infusion over 1 h via
a central venous line (0.25 or 1.0mg/kg. The volume of col-
chicine solution varied according to the pig’s body mass.
Animals received an infusion of 5mL/kg/h 0.9% sodium
chloride during the study, increased as clinically required.
Norepinephrine (4mg/100mL solution) was given IV if the
mean arterial pressure (MAP) fell below 45mmHg and did
not respond to fluid resuscitation.
In the Fab fragment studies, to fully neutralise the
0.25mg/kg colchicine challenge, 12.5mL/kg (e.g. 375mL for a
30 kg animal) of Fab fragments were administered. The single
clinical case in the literature reported cardiovascular improve-
ment and impressive PK response (marked redistribution of
colchicine into the blood) to Fab given 40 h after exposure
[12]. Being conservative, but wishing to select a clinically
relevant time point for administration, we first chose to give
Fab 7 h after the start (and 6 h after the end) of the colchi-
cine infusion. The dose was split into two, with one half
given over 1 h followed by the second half over 6 h, to
reduce wastage in the urine of free Fab, unbound to colchi-
cine (as done for digoxin specific Fab) [19,20]. Since this
proved ineffective, in further studies, to increase the likeli-
hood of success, the full neutralising dose was given earlier
and administered over 1 h.
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Sampling. Arterial blood samples were taken for pharma-
cokinetic analysis at 30 and 10min prior to colchicine, at
5, 10, 15, 30, 45, 60 and 90min post dosing, and then at 2, 4,
and 4 h intervals until 24 h, and 8 hourly thereafter until the
animal’s euthanasia. The sample was transferred to an EDTA-
containing tube, centrifuged for 7min at 3900 rpm, and the
plasma stored frozen at 20 C until analysis.
Arterial blood gasses and clinical chemistry were moni-
tored on an EPOC blood analyser (Woodley Equipment
Company Ltd, UK) pre-treatment and at 30, 60 and 90min, 2
and 4-h post-dosing, and at 4-h intervals thereafter. Blood
chemistry was checked pre-treatment and at 8-h intervals
post treatment; hematology including prothrombin times
was checked pre-treatment and at 12-h intervals thereafter.
Blood samples were taken pre-treatment, after 24 h, and
immediately before euthanasia, for microbiology studies).
Urine was collected at 3 h intervals throughout the study
through an indwelling bladder catheter. Urine from the previ-
ous three hours was mixed and two 10mL samples taken off
and immediately frozen.
Samples of heart (left ventricle), muscle (tibialis cranialis),
liver, lung, and small intestine were taken post-mortem and
stored in formal saline before histological analysis.
Euthanasia. Animals were given an overdose of IV sodium
pentobarbital whilst under isoflurane anaesthesia either at
the end of the planned study (48 h) or when their MAP fell
below 45mmHg for 30min and continued to fall without
sign of recovery despite fluids and vasopressors.
Statistical analysis
Formal power calculations could not be performed due to a
lack of data for the effect of colchicine in pigs. Primary data
analysis was done in Prism 7.0 (GraphPad, CA). All animals
were included in the analysis. Pig weights, clinical and bio-
chemical outcomes were summarized with mean and SD.
Time to euthanasia was assumed not to be normally distrib-
uted and hence is described with median and interquartile
range (IQR), while acknowledging the small sample size.
Individual animal data are provided to explicitly illustrate
time to euthanasia.
Measurement of colchicine concentrations
Free and Fab-bound colchicine was measured using a LC-MS/
MS method, as published [21]. Briefly, free colchicine was
separated from Fab-bound colchicine using 30 KDa microfil-
ters. Total colchicine was determined after Fab denaturation
by dilution in water and heating at 100 C for 1 h. Deuterated
colchicine was used as internal standard. Samples were then
processed by liquid-liquid extraction before LC-MS/MS ana-
lysis. Calibration curves were designed over the concentra-
tion range 0.5–100 ng/mL for plasma and urine.
Measurement of anti-colchicine fab fragment
concentrations
An ELISA was developed to measure Fab concentrations in
plasma and urine. Calibration curves (0.01–0.5mg/L) were
generated using sheep IgG Fab fragments (Rockland
Immunochemicals) as standards. Accuracy and precision were
controlled using three levels of quality control (QC) samples
(0.03, 0.08 and 0.125mg/L). Standards and QC were prepared
in porcine plasma. Well plates were coated with 2mg/L of
rabbit anti-sheep IgG F(ab’)2 fragments (Jackson
ImmunoResearch, West Grove). Fab standards and samples
were added on corresponding wells. After 1 h incubation at
37 C, peroxidase-conjugated rabbit anti-sheep IgG F(ab’)2
was added and plates incubated for 30min at 37 C. Plates
were washed, 3,30,5,50-tetramethylbenzidine added, incubated
for 15min, and a stop solution (HCl 1M) added. Absorbance
was measured using a POLARstar omega plate reader (BMG
Labtech, Ortenberg, Germany) at 450 nm.
Pharmacokinetic analysis
Plasma colchicine and Fab concentration time data were ana-
lysed using the MicroPharm Kinetics 5.0 software, using a
two-compartment models. The log linear concentration time
data were fitted by linear regression analysis to obtain the
volume of distribution; terminal disposition constants (a and
b) were calculated by mean square regression analysis.
Distribution and terminal half-lives (respectively, t1/2a and
t1/2b) were calculated as ln2/a and ln2/b. AUC0–20h and
AUC0–end were calculated by use of the linear trapezoidal
rule. AUC0–1 was calculated for Fab by adding to AUC0–48
the value of the last measured plasma concentration divided
by terminal disposition rate constant. QU0–20 and QU0–48 are
the cumulated amounts of unchanged colchicine excreted in
the urine from the time 0–20 and 0–48 h, respectively.
Funding
The funders had no role in study design, data collection,
data interpretation, or writing of the report. Micropharm staff
performed the measurement of plasma Fab concentrations
but the PK analysis was done by others. The authors had full
access to all the study data; all agreed with the decision to
submit for publication. The first author (ME) guarantees the
data within the paper.
Results
Oral colchicine administration
We first attempted to identify an oral dose of colchicine that
would cause severe toxicity, matching human poisoning after
ingestion of colchicine tablets. In a dose-ranging study, four
pigs were randomly administered 0.5 or 1.0mg/kg of colchi-
cine in solution by oral gavage and studied for 60 h. This did
not result in a reproducible model, with variable PK profiles
for plasma colchicine concentration and no dose–response in
the time-to-euthanasia (Figure 1).
The animals did, however, show evidence of multi-organ
injury and severe cardiotoxicity. Cardio-respiratory function
was not affected by colchicine until late in the poisoning
(Figure 2). In three of four pigs (two 0.5mg/kg, one
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1.0mg/kg), cardiotoxicity developed with a fall in MAP requir-
ing norepinephrine. The doses of norepinephrine required to
maintain an MAP> 45mmHg increased rapidly over a few
hours before both heart rate and MAP fell precipitously over
minutes (Figure 2) and the animals were euthanised. The
fourth (2nd high dose) animal began to develop cardiotoxic-
ity after 53 h; norepinephrine requirements rose more slowly
than with the other animals. It was euthanised as severe car-
diotoxicity developed at 56.5 h.
Clinical biochemistry analyses showed evidence of liver
(raised AST activity) and muscle (raised CK activity) injury
after 15 h as well as late renal injury in the hours before
euthanasia (data not shown).
Intravenous colchicine administration
To seek a more reliable model, we switched to the IV route
of administration for the next four pigs (a route previously
used for clinical therapy [7]). To compensate for increased
colchicine bioavailability after IV administration [8], the lower
dose was halved to 0.25mg/kg while a higher dose was kept
at 1.0mg/kg with the ambition of bracketing severe toxicity.
The colchicine was infused over one hour.
The first two pigs received 0.25 and 1.0mg/kg by IV infu-
sion. Because toxicity was rapid for the higher dose, with
euthanasia required at 14.5 h, the next two animals received
0.25mg/kg IV.
Colchicine PK was similar in the three animals receiving
0.25mg/kg, with a mean AUC0–20 of 343 mg/L/h (SD¼ 21 mg/
L/h), t1/2a of 0.21 h (SD¼ 0.012 h) and QU0–20 of 17%
(SD¼ 2.9%) (Figure 3; Table 1). In the animal receiving the
higher dose, AUC0–16 was 2,398 mg/L/h and t1/2a 0.15 h. The
elimination half-life could not be calculated because of a
plateau in plasma colchicine concentration from 8h post-
administration to time of euthanasia.
Toxicity was consistent in the three animals receiving
0.25mg/kg, with euthanasia required a mean of 22.5 (SD 3.2)
h after starting the infusion (Figure 4). Animals showed
evidence of dose-related liver, renal and muscle toxicity
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Figure 1. (A) Plasma colchicine concentration and (B) time to euthanasia for animals receiving 0.5mg/kg (blue circles) or 1.0mg/kg (red squares) colchicine by oral
administration.
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(Figure 5), as well as late, severe cardiotoxicity. Blood gas
analysis showed no effect on arterial pH but a substantial
rise in arterial lactate concentration, peaking at 7–9mmol/L
(Figure 6). No bacteria were cultured from samples taken for
microbiology. Histology showed moderate, diffuse necrotizing
enteritis of the small intestine, mild cardiac myopathy, and
pulmonary alveolar and interlobular oedema.
The IV dose of 0.25mg/kg colchicine was selected to
study the effect of anti-colchicine Fab.
Administration of anti-colchicine fab to colchicine
poisoned pigs
A full neutralising dose of anti-colchicine Fab given from 6h
after completion of the colchicine infusion (50% over 1 h,
50% of the next 6 h) produced a 7.35-fold increase in plasma
colchicine (AUC0–20 2,522 [SD¼ 14] mg/L/h) and removed all
free colchicine during the infusion (Figure 4). However, it did
not increase urinary elimination of colchicine (QU0–20 18%,
mean of 1.1-fold greater than controls) and did not prevent
toxicity or markedly improve outcome—euthanasia was
required a mean of 29.1 (SD 3.4) h after starting the
colchicine.
Infusion over 1 h of a full neutralising dose of anti-colchi-
cine Fab, 1 and 3 h after the end (2 and 4 h after the start) of
the colchicine infusion, markedly increased both plasma col-
chicine and urinary elimination of colchicine. The Fab pro-
duced 12.9-fold (mean AUC0–20 4,433 [SD¼ 607] mg/L/h) and
6.0-fold (AUC0–20 2,047 [SD¼ 51] mg/L/h) increases in plasma
colchicine, as well as 2.5-fold (QU0–20 42.5 [SD¼ 6.4] %) and
2.1-fold (AUC0–20 36.5 [SD¼ 0.7] %) increases in urinary col-
chicine elimination, respectively.
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Figure 3. Plasma pharmacokinetics for total colchicine and free colchicine in animals receiving intravenous colchicine (0.25mg/kg), with or without anti-colchicine
Fab, according to delay to treatment. Control animals received no Fab after IV colchicine 0.25mg/kg over 1 h¼ blue squares. Animals received Fab at 6 h post-infu-
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purple triangle; free colchicine: purple circle).
Table 1. Pharmacokinetics of colchicine and Fab.
Colchicine administered IV 0.25mg/kg
Fab infusion Controls
From 1 h after
the colchicine
infusion
From 3 h after
the colchicine
infusion
From 6 h after
the colchicine
infusion
Animals n¼ 3 (mean ± SD) n¼ 1 n¼ 1 n¼ 1 n¼ 1 n¼ 1 n¼ 1
AUC0–20H (mg L
1 h1) 343 ± 21 4862 4004 2011 2083 2532 2512
Free colchicines AUC0–20 (mg L
1 h1) 389 259 298 285 300 220
AUC0–end (mg L
1 h1) 3741 5313 3142 3343 3182 2971
Ratio (AUC0–20/AUC0–20 control) 1 14.1 11.6 5.8 6.1 7.4 7.3
t1/2a (h) 0.21 ± 0.12 — — — — 0.21 0.19
t1/2b (h) — 9.7 9.0 11 11 — —
QU0–20h 17 ± 2.9% 38% 47% 37% 36% 18% 18%
QU0–end 43% 56% 43% 43% 18% 20%
Ratio (QU0–20/QU0–20 control) 1 2.2 2.8 2.2 2.1 1.1 1.1
Fab AUC0-1 (g L
1 h1) — 40.0 32.4 28.2 31.9 — —
Fab t1/2a (h) — 2.3 2.6 1.6 1.3 — —
Fab t1/2b (h) — 44.4 31.3 22.1 11.5 — —
The Fab infusions given 1 and 3 h after the colchicine infusion were administered over 1 h; the Fab infusion given 6 h after the col-
chicine infusion finished was administered over 7 h (50% over first hour, 50% over following 6 h).
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This increased extraction of colchicine from the tissues
and elimination was associated with markedly reduced tox-
icity, with all four animals surviving to 48 h (Figure 4) and
none showing marked cardiotoxicity and cardiovascular
decompensation (as seen for animals not receiving Fab—see
Figure 2) (data not shown). Clinical biochemistry showed
reduced liver, kidney and muscle injury (Figure 5). Blood gas
analysis showed no effect on arterial pH or lactate concentra-
tion, except for transient rise in lactate to 5mmol/L in one
animal receiving Fab 1 h after the end of the colchicine infu-
sion (Figure 6). No bacteria were cultured from samples taken
for microbiology. Histology showed mild necrotizing enteritis
of the small intestine, mild cardiac myopathy, and mild pul-
monary alveolar and interlobular oedema.
The Fab had a mean t1/2a of 2.0 (SD 0.6) h and mean t1/2b
of 27.3 (SD 14.0) h (Table 1). The half-life of elimination was
slow enough in all animals to keep concentrations of free
plasma colchicine undetectable until 20 h and at very low
concentrations until the end of each study.
Discussion
This study has shown that early administration of anti-colchi-
cine Fab fragments redistributes colchicine from extracellular
fluid to the blood and increases its elimination in the urine;
this removal of colchicine from the tissues, if the Fab is given
sufficiently early, in sufficient dose, prevents colchicine-
induced cardiotoxicity, multi-organ injury, and metabolic
acidosis. Although a small translational study, the results sug-
gest that anti-colchicine Fab may benefit patients with col-
chicine toxicity if given early enough after exposure.
Administration of a full neutralising dose of Fab within 3 h
of the end of colchicine administration resulted in marked
increases in plasma colchicine and urinary elimination, and
absence of free colchicine from plasma until 20 h after colchi-
cine exposure. Delay of Fab administration to 6 h after the
end of colchicine administration, and administration of a
half-neutralising dose, resulted in effective redistribution—
similar to that following Fab started at 3 h—but a less clear
effect on urinary elimination and only a modest increase in
time to euthanasia. Although this poor delayed effect may
be due to the Fab dose administered, our results from IV
dosing may suggest that colchicine Fab will be clinically rele-
vant for relatively few patients since many present to hos-
pital after 6 h [5,6].
This possible lack of effectiveness after only a few hours
contrasts with the single report of a patient treated with
goat anti-colchicine antibodies which showed both PK and
clinical benefit when receiving Fab 40 h after ingestion [12].
This difference might be because porcine colchicine poison-
ing is not a perfect model of human poisoning, with differen-
ces between pigs and humans in cardiovascular function and
metabolism. However, we found the lethal dose in pigs to be
similar to that reported for humans, and far lower than the
rat LD50 (>25mg/kg), consistent with some relevance of pig
poisoning for modelling human poisoning. Multi-organ injury
seen in the model also replicated human poisoning. The
polyclonal Fab had very high affinity for colchicine (average
affinity constant 3.16 1011 M1) suggesting that differences
in affinity between the goat antibody used for the clinical
case (affinity 2.0 1010 M1) and the ovine Fab used here is
not responsible for the differences in effect. It is also possible
that the pharmacokinetics of the ovine Fab in this pig model
are quite different to that of the goat Fab used in the clinical
case [12].
Unfortunately, oral colchicine dosing did not produce reli-
able PK or model poisoning well, likely due to variation in
absorption of the colchicine from the anaesthetised pig gut.
This variability was not noted in our previous studies of oral
dimethoate organophosphorus insecticide toxicity [18], prob-
ably due to the lower toxicity of the insecticide and therefore
much higher doses needed for poisoning (1000mg/kg).
This pig study suggests that humans will have to be
treated soon after poisoning for the Fab to be effective. This
might be true for very high doses but not for more border-
line doses. Increasing the number of animals studied with IV
colchicine at different delays to Fab is unlikely to yield fur-
ther information on timing and doses for colchicine tablet
poisoning. Intravenous infusions over 1 h may not accurately
reflect oral poisoning despite similar Cmax and bioavailability.
The slower absorption and distribution to tissues, and direct
effect on gut enterocytes, of oral administration may allow
the Fab longer to work in human poisoning [22].
Instead, a clinical study is needed that treats all patients
presenting to hospital with colchicine poisoning up to 48 h
after exposure, stratified according to time to treatment, esti-
mated dose ingested, and plasma colchicine concentration
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Figure 4. Time to euthanasia in animals receiving intravenous colchicine with
or without anti-colchicine Fab, according to delay to treatment.
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before treatment. Due to the scarcity of cases, the study will
need to be observational. Such a study is now being started
in France, based on the data on redistribution reported in
this porcine study. As patients are studied, and outcomes
recorded, the time to treatment could be slowly shortened
down to 6, 12 or 24 h. Alternatively, all patients could in
future be treated with the understanding that only border-
line cases will get any benefit after a certain time.
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The pharmacokinetics of colchicine and Fab in the pigs
were generally similar to those reported in humans. The dis-
tribution half-life of colchicine (0.21 h) and of Fab (2.0 h) in
this porcine study were similar to that observed in humans
(colchicine 0.15 h, anti-digoxin Fab 0.5–1.9 h) [21,23].
Distribution was complete one hour after the end of infusion,
consistent with the best response to Fab occuring when it
was started at 1 h. Fab administration increased the AUC 6 to
14-fold compared to controls, similar to that noted in colchi-
cine intoxicated rabbits (19-fold) [24]. The elimination half-
lives (9.0–11.0 h) calculated in the last four pigs were shorter
than observed in humans receiving IV colchicine infusions
(30 ± 6 h). In the same way, elimination half-life (11.5–44.4 h)
was comparable to half-life in human (11.0–34.5 h) exhibiting
a high variability.
Limitations
We used a PK dose–response approach to minimise the num-
ber of animals used in the study before moving into human
studies. Despite being a small study, robust dose/time-
response effects were seen in terms of the AUC, time to
euthanasia, and reduction in organ injury. Since the study
has provided proof of binding in vivo in a clinically relevant
model that is now leading to clinical trials, use of further ani-
mals is unlikely to provide additional useful data. We
acknowledge that there are cardiovascular and metabolic dif-
ferences between pigs and humans—such as basal heart rate
and mass of the liver and kidneys—that might make pigs
more sensitive to cardiotoxicity, reducing effectiveness com-
pared to humans. However, additional pig studies will not
help guide human treatment.
We used IV infusions of colchicine over 1 h to simulate
oral dosing due to the unreliable PK of oral colchicine in the
anaesthetised pigs. This difference might be important
although the bioavailability of oral tablets is similar to IV
infusions [5,6]. The animals receiving Fab at 6 h received only
half a neutralising dose over the first hour, followed by the
second half dose over 6 h. It is therefore not possible to dir-
ectly compare the results with the 1 and 3 h delays to admin-
istration. However, redistribution was similar to that after a
3 h delay, despite the lack of effect on severity. This informa-
tion is useful and reinforces the need for a large clinical
study to identify the latest possible treatment time in human
patients. The IV dose of 0.25mg/kg was selected as an appar-
ently reliable lethal dose of colchicine; we did not explore
further doses between 0.25 and 1.0mg since our aim was to
rapidly move into human studies once we had tested
whether the Fab could bind and redistribute colchicine with
clinical effect in vivo in the pig.
Conclusion
In this clinically relevant porcine model of colchicine poison-
ing, anti-colchicine Fab fragments were highly effective at
stopping toxicity if given early enough in a large enough
dose. Clinical trials are required to translate this knowledge
into human patients.
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